New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2014
20:04 EDTICPTIntercept reports additional positive data from POISE trial at EASL
Intercept Pharmaceuticals announced efficacy and safety results from the Phase 3 POISE trial of obeticholic acid, OCA, for the treatment of primary biliary cirrhosis, PBC, to be presented in a late-breaker session at the International Liver Congress of the European Association for the Study of the Liver, EASL. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR in development for PBC, nonalcoholic steatohepatitis, NASH, and other liver and intestinal diseases. As previously reported, the POISE trial met its primary endpoint with high statistical significance, demonstrating OCA's efficacy on a composite liver biochemical endpoint which has been shown to strongly correlate with improved clinical outcomes. The proportion of patients meeting the POISE primary endpoint was: 10% in the placebo group, 47% in the 10 mg OCA group and 46% in the 5-10 mg OCA group. New data in the presentation show that OCA treated patients achieved a highly statistically significant reduction in alkaline phosphatase, ALP, as early as two weeks, with a peak effect achieved by six months.Pruritus, generally mild to moderate, was the most frequently reported adverse event in the POISE trial. However, only 1% of the patients in the OCA 5-10 mg titration group discontinued therapy due to pruritus after moving up to the 10 mg dose, as compared to seven, 10%, of the patients in the 10 mg OCA group. Additional data presented show that the incidence and severity of OCA related pruritus diminishes with time on therapy. Specifically, pruritus scores were no different from placebo in both OCA treatment groups during the second half of the trial.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
07:46 EDTICPTIntercept Pharmaceuticals volatility at low end of historic range
Subscribe for More Information
August 18, 2014
10:57 EDTICPTOptions with decreasing implied volatility
Subscribe for More Information
August 15, 2014
17:02 EDTICPTStocks end week slightly higher despite flare-up in Russian tensions
Subscribe for More Information
10:41 EDTICPTOptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT UVXY MNKD KING VIX SVXY VXX RAX OPK
10:01 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:32 EDTICPTIntercept started with Underperform, $172 target at FBR Capital
FBR Capital initiated shares of Intercept with an Underperform rating and $172 price target. The stock closed yesterday at $296.36. FBR believes investors are too optimistic on the nonalcoholic steatohepatitis market and the company's path to commercialization for its obeticholic acid. The firm thinks Intercept may face payor pushback and restriction as its drug will be competing with hepatitis C treatments for dollars.
06:16 EDTICPTIntercept initiated with an Underperform at FBR Capital
Subscribe for More Information
August 14, 2014
11:46 EDTICPTOptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTICPTOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use